Galderma Acne Ingredient Switch Receives NDAC Review In April
This article was originally published in The Pink Sheet Daily
FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.
You may also be interested in...
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
FDA threw the switch floodgates open with the NSURE initiative and it has fueled interest with the recent first-in-class switches of Nasacort and Oxytrol for Women. Likely categories for successful switches include dermatology, nasal sprays in allergy, sleep, migraine relief and cholesterol management.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.